OncoCyte Corporation (OCX)

OncoCyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1.38	1.5	0.96	2.2	1.22	0
Revenue Growth (YoY)	57.94%	56.89%	-56.41%	80.76%	-	-
Cost of Revenue	1.08	1.09	0.98	0.78	1.86	0
Gross Profit	0.31	0.41	-0.02	1.42	-0.64	0
Selling, General & Admin	13.39	13.98	23.01	22.84	23.28	15.45
Research & Development	9.34	9.29	7.3	5.04	9.8	6.79
Other Operating Expenses	17.83	2.28	-12.34	27.27	-4.01	0
Operating Expenses	40.56	25.55	17.98	55.15	29.07	22.24
Operating Income	-40.25	-25.14	-18	-53.73	-29.71	-22.24
Interest Expense / Income	0.06	0.05	0.08	0.21	0.25	0.3
Other Expense / Income	-0.16	2.59	54.82	19.42	1.22	-0.11
Pretax Income	-40.15	-27.78	-72.9	-73.36	-31.19	-22.43
Income Tax	0	0	0	-9.26	-1.25	0
Net Income	-40.15	-27.78	-72.9	-64.1	-29.93	-22.43
Preferred Dividends	0.71	0.94	0.52	0	0	0
Net Income Common	-40.86	-28.72	-73.42	-64.1	-29.93	-22.43
Shares Outstanding (Basic)	8	8	6	4	3	3
Shares Outstanding (Diluted)	8	8	6	4	3	3
Shares Change	38.59%	38.10%	24.61%	35.80%	27.65%	35.52%
EPS (Basic)	-5.08	-3.75	-13.25	-14.40	-9.20	-8.80
EPS (Diluted)	-5.08	-3.75	-13.25	-14.40	-9.20	-8.80
Free Cash Flow	-17.43	-23.25	-49.91	-38.19	-27.21	-20.63
Free Cash Flow Per Share	-2.11	-3.04	-9.01	-8.59	-8.31	-8.04
Gross Margin	22.07%	27.48%	-1.88%	64.60%	-52.55%	-
Operating Margin	-2912.66%	-1672.39%	-1878.60%	-2444.27%	-2443.34%	-
Profit Margin	-2956.66%	-1911.04%	-7664.09%	-2916.15%	-2461.51%	-
Free Cash Flow Margin	-1261.51%	-1547.04%	-5209.60%	-1737.40%	-2237.42%	-
EBITDA	-38.55	-26.05	-67.6	-68.94	-30.54	-21.78
EBITDA Margin	-2789.36%	-1733.13%	-7056.26%	-3136.67%	-2511.51%	-
Depreciation & Amortization	1.54	1.68	5.22	4.21	0.39	0.35
EBIT	-40.09	-27.73	-72.82	-73.15	-30.93	-22.13
EBIT Margin	-2901.01%	-1844.91%	-7601.15%	-3327.98%	-2543.91%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).